DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for atrophic gastritis — screening already-approved drugs against its 26-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAtrophic gastritis maps to a 26-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for atrophic gastritis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
MLLT3 super elongation complex subunit (MLLT3) — MLLT3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8PJ7 · 1.26 Å · ligand ~{N}-[(1~{R})-2,3-dihydro-1~{H}-inden-1-yl]-5-[4-(dimethylcarbamoyl)-3-oxidanyl-phenyl]-1,2-oxazole-3-carboxamide (ZJ9). Experimental structure, not a prediction.
What the evidence adds up to
In 1982, nitrite and nitrosamine concentrations were measured in 108 patients undergoing gastroscopy. Among 19 patients with atrophic gastritis, the concentrations of nitrite and nitrosamines were significantly elevated compared with all other groups, which included 26 normal subjects, 20 patients with duodenal ulcer, 11 with benign gastric ulcer, and 32 with inflammatory changes of the gastric mucosa. The authors suggested a relationship between constant exposure of already damaged gastric mucosa to N-nitroso compounds and the known high incidence of gastric cancer in atrophic gastritis. A 1979 review noted that atrophic gastritis consists of chronic inflammation and atrophy of the gastric mucosa, that the circumstances leading to it are not clear, and that factors such as alcohol, salicylates, and bile reflux are not commonly implicated in its pathogenesis.
A 2018 study selected 96 patients with chronic atrophic gastritis and divided them into a control group given routine treatment and an observation group given teprenone on top of routine treatment, 48 patients per group. The observation group had a better pathological score than the control group (P<0.05), a shorter mean hospital stay (6.65±0.85 days vs. 13.54±2.74 days, P<0.05), and a higher clinical effective rate (95.83% vs. 77.08%, P<0.05). The authors concluded that teprenone could be used in treatment and helped improve pathological scores, reduce hospital time, and improve clinical effect.
No other drugs are mentioned in these abstracts. The 2018 study is small, single-centre, and used sequential allocation rather than randomisation, so its results are not reliable evidence of efficacy. What is still missing is a properly randomised, blinded trial with adequate sample size, long-term follow-up for cancer incidence, and clear patient stratification by severity and subtype of atrophic gastritis.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Scandinavian Journal of Gastroenterology · 1982 · 42 citations
Nitrite and Nitrosamines in Gastric Juice: Risk Factors for Gastric Cancer?
AbstractNitrite and nitrosamine concentrations have been measured in 108 patients undergoing gastroscopy as a part of routine gastrointestinal investigations. The nitrite and nitrosamine values of 20 patients with duodenal and 11 patients with benign gastric ulcer were within the range of the values of 26 normal subjects. The nitrite and nitrosamine concentrations in 32 patients with inflammatory changes of the gastric mucosa were slightly higher than normal values and correlated with the progressive degrees of the severity. In 19 patients with atrophic gastritis the concentrations of nitrite and nitrosamines were significantly elevated in comparison with those of all other groups. Our data suggest a relationship between the constant exposure of an already damaged gastric mucosa to N-nitroso compounds and the known high incidence of gastric cancer in atrophic gastritis.
New England Journal of Medicine · 1979 · 23 citations
Illuminating the Antrum
AbstractAtrophic gastritis consists of chronic inflammation and atrophy of the gastric mucosa. As the atrophy of gastric glands progresses, particularly in pernicious anemia, a heavy cellular infiltrate of lymphocytes and plasma cells persists.1 The circumstances leading to atrophic gastritis are not clear. Some cases begin as superficial gastritis, but in many the disease starts and progresses silently.2 Although acute and chronic superficial gastritis are associated with peptic-ulcer disease, severe physical stress, ingestion of alcohol and salicylates or reflux of bile into the stomach (in benign gastric ulcer and after antrectomy), these factors are not commonly implicated in the pathogenesis of . . .
Clinical experience of gastroenterology in patients with chronic atrophic gastritis
AbstractObjective
To explore the clinical effect of chronic atrophic gastritis in department of gastroenterology.
Methods
A total of 96 patients with chronic atrophic gastritis treated in our hospital from February 2017 to February 2018 were selected and were divided into the control group and the observation group according to the order of the hospital, 48 cases in each group. The control group were given routine treatment, and the observation group was given teprenone on the basis of the control group. The therapeutic effect and the rate of adverse reactions of the two groups were observed.
Results
The pathological score of the patients in the observation group was better than that in the control group (P<0.05); the time of hospitalization in the observation group was shorter than that in the control group [(6.65±0.85)d vs.(13.54±2.74)d] (P<0.05); the effective rate of clinical treatment in the observation group was higher than that in the control group (95.83% vs.77.08%) (P<0.05).
Conclusions
Chronic atrophic gastritis has certain particularity, it should be targeted in the treatment of chronic atrophic gastritis. Tepradone is an effective drug, it can be used in the treatment of chronic atrophic gastritis patients. It is helpful to optimize the pathological score of patients, reduce the time of hospitalization, and improve the clinical treatment effect.
Key words:
Chronic atrophic gastritis; Department of gastroenterology; Effective rate
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
